For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis.

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Ambulatory acute kidney injury is common among individuals with cirrhosis and is associated with a high 90-day mortality.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Early-life factors are associated with body mass index trajectories in children, with risk for obesity detectable at age 3.5 years.

Experienced weight stigma improves from pre- to post-metabolic bariatric surgery, according to a recent study.

Growth hormone was not associated with a lower risk for the composite liver outcome among patients with adult-onset craniopharyngioma.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Patients with IBD in rural areas are significantly less likely to receive advanced therapies and multidisciplinary care compared with their urban counterparts.

More than one-third of patients with SSc screened positive for self-reported depression, with GI involvement identified as the most significant predictor.